Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J
Trends Immunol. 2001 Mar;22(3):113-5. doi: 10.1016/s1471-4906(00)01824-x.
In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.
在癌症临床前模型中,白细胞介素12(IL-12)基因疗法与免疫疗法(如其他细胞因子和/或趋化因子的基因转移、共刺激分子或过继性细胞疗法)联合使用时,已取得了前所未有的成功。已发现这些联合疗法产生的是协同效应而非相加效应。同时,IL-12基因疗法已开始作为单一药物进行临床试验,但联合策略也即将出现。